127732-35-8

Basic information

• Product Name: 2-[5-Methoxy-2-(4-{methyl-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-amino}-butoxy)-phenyl]-4-methyl-4H-benzo[1,4]thiazin-3-one
• Synonyms: 2-[5-Methoxy-2-(4-{methyl-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-amino}-butoxy)-phenyl]-4-methyl-4H-benzo[1,4]thiazin-3-one
• CAS NO: 127732-35-8
• Molecular Weight: 580.745
• Mol File: 127732-35-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-[5-Methoxy-2-(4-{methyl-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-amino}-butoxy)-phenyl]-4-methyl-4H-benzo[1,4]thiazin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[5-Methoxy-2-(4-{methyl-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-amino}-butoxy)-phenyl]-4-methyl-4H-benzo[1,4]thiazin-3-one(127732-35-8)
• EPA Substance Registry System: 2-[5-Methoxy-2-(4-{methyl-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-amino}-butoxy)-phenyl]-4-methyl-4H-benzo[1,4]thiazin-3-one(127732-35-8)

Safety Data

• Hazardous Substances Data: 127732-35-8(Hazardous Substances Data)

Upstream product

• 93848-37-4 3,4-Dihydro-2-(2-hydroxy-5-methoxyphenyl)-4-methyl-3-oxo-2H-1,4-benzothiazine 
• 4838-96-4 N-methyl-3,4,5-trimethoxyphenethylamine 
• 93848-32-9 2-[2-(4-Bromo-butoxy)-5-methoxy-phenyl]-4-methyl-4H-benzo[1,4]thiazin-3-one 

Relevant articles and documents

Synthesis and Ca2+ Antagonistic Activity of 2--5-methoxyphenyl>-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazines

As an extension of the previous investigation (J.Med.Chem. 1988, 31, 919), we synthesized a series of 2-5-methoxyphenyl>-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazines (3) and evaluated their Ca2+ antagonistic activities.Ca2+ antagonistic activity was measured with isolated depolarized guinea pig taenia cecum.On the basis of their potent Ca2+ antagonistic activity, six benzothiazines were selected and further evaluated for their vasocardioselectivity.Among these six compounds, the key compound 15 ethyl>amino>propoxy>phenyl>- 4-methyl-3-oxo-2H-1,4-benzothiazine hydrogen fumarate was recognized as having the lowest cardioselectivity.Following optical resolution, the absolute configuration of the compound's optically active enantiomer was determined by means X-ray crystallography of a synthetic precursor (+)-4a.The Ca2+ antagonistic activity of 15 was found to reside primarily in (+)-15 (which was about 7 times more potent than (-)-15).The in vitro study showed that (+)-15 had a low cardioselectivity compared to verapamil and diltiazem.This result suggests that (+)-15 would exhibit less adverse effects due to cardiac inhibition than diltiazem and verapamil in therapeutic use.